Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide

S. Ricci et al., Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide, ANN ONCOL, 11(9), 2000, pp. 1127-1130
Citations number
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
ISSN journal
0923-7534 → ACNP
Year of publication
1127 - 1130
SICI code
Background: In the present study we investigated the efficacy and tolerabil ity of i.m. octreotide acetate (octreotide LAR) in patients with metastatic neuroendocrine tumors (NETs) previously treated and failed on i.m. lanreot ide. Patients and methods: Fifteen patients (8 females, 7 males, median age 67 y ears, range 28-81 years) with metastatic NETs (8 endocrine pancreatic tumor s, 7 midgut carcinoids) were enrolled in the study. All patients were in pr ogressive disease (objective: 11 patients, symptomatic: 10 patients, bioche mical: 11 patients) after treatment with slow release lanreotide, 30 mg eve ry 14 days for a median time of 8 months (range 3-19 months). All patients had measurable disease; 12 patients had elevated serum and/or urine markers and 11 were symptomatic. Octreotide scintigraphy was positive in 13 of 15 patients. Octreotide LAR was administered as i.m. injection at the dose of 20 mg every four weeks until disease progression. Results: An objective partial response (PR) was documented in one patient ( 7%), no change (NC) in six (40%), and progressive disease (PD) in eight pat ients (53%). The PR was observed in one patient with non-functioning endocr ine pancreatic tumor with progressive liver and lymph node metastases after 16 months of i.m. lanreotide therapy. The median duration of disease stabi lization was 7.5 months (range 6-12+ months). The overall biochemical respo nse rate was 41%, including CRs (33%) and PRs (8%); biochemical responses w ere observed in carcinoids as well as in endocrine pancreatic tumors; the m edian duration of response was 5 months for CRs and 7.5 months for PRs. The overall symptomatic response rate was 82%. The median duration of response for diarrhoea, abdominal pain, or both was 6.5 months (range 3-12+ months) . Improvement in performance status (PS) was obtained in 5 of 11 patients w ith PS of 1 at study entry. Median duration of octreotide LAR treatment was seven months (range 3-12+ m onths). No serious adverse events were reported; mild side effects were rep orted in 26% of patients. Conclusions: Octreotide LAR 20 mg shows significant efficacy in terms of ob jective response rate (PR + SD), biochemical and symptomatic control in pat ients with metastatic NETs of the GEP system pretreated and progressing on slow release lanreotide.